Pharma News

Top developments in biosimilars during 2016

Published in: Volume 6 / Year 2017 / Issue 1
Author(s):
Page: 42-7

Submitted: 27 January 2017; Revised: 31 January 2017; Accepted: 1 February 2017; Published online first: 6 February 2017 Previous years have been momentous for biosimilars [1] and 2016 is no… Read More »

The anti-TNF biosimilar CT-P13 had comparable efficacy to infliximab in rheumatoid arthritis over one year

Published in: Volume 5 / Year 2016 / Issue 2
Author(s):
Page: 96

Submitted: 24 May 2016; Revised: 8 June 2016; Accepted: 10 June 2016; Published online first: 24 June 2016 The introduction of biologicals has revolutionized the treatment of immune-mediated diseases such… Read More »

Switching from the infliximab reference product to CT-P13 in patients with rheumatoid arthritis or ankylosing spondylitis: results of the PLANETAS and PLANETRA extension studies

Published in: Volume 5 / Year 2016 / Issue 2
Author(s):
Page: 94-5

Submitted: 24 May 2016; Revised: 8 June 2016; Accepted: 10 June 2016; Published online first: 24 June 2016 CT-P13, also known by its brand names Remsima or Inflectra, is a… Read More »

Top developments in biosimilars during 2015

Published in: Volume 5 / Year 2016 / Issue 1
Author(s):
Page: 42-4

Submitted: 14 January 2016; Revised: 26 January 2016; Accepted: 27 January 2016; Published online first: 9 February 2016 Once again the biosimilars industry has had a busy year [1]. Perhaps… Read More »

Top developments in biosimilars during 2014

Published in: Volume 4 / Year 2015 / Issue 1
Author(s):
Page: 42-7

Submitted: 10 February 2015; Revised: 24 February 2015; Accepted: 25 February 2015; Published online first: 6 March 2015 The past year has once again been a busy one for the… Read More »

Reducing the European healthcare budget with generics and biosimilars

Published in: Volume 3 / Year 2014 / Issue 4
Author(s):
Page: 200-1

The world market for medicinal products is expected to reach US$1 trillion in 2014. Global spending on medicines is expected to grow to nearly US$1.2 trillion by 2017 [1]. As… Read More »

International Alliance of Patients’ Organizations toolkit for biological and biosimilar medicines

Published in: Volume 3 / Year 2014 / Issue 4
Author(s):
Page: 199-200

The International Alliance of Patients’ Organizations (IAPO) is an alliance of over 200 patient groups that represents the interests of patients worldwide. In November 2013, IAPO published its Information and… Read More »

ECCO 2013 survey highlights lack of confidence in biosimilars

Published in: Volume 3 / Year 2014 / Issue 3
Author(s):
Page: 154

Results of a survey carried out by the European Crohn’s and Colitis Organisation (ECCO) highlight a lack of confidence in biosimilars and the need for continued education. The results of… Read More »

New EU guidance for the evaluation of medicinal products with modified drug release will be finished by the middle of 2014

Published in: Volume 3 / Year 2014 / Issue 2
Author(s): ,
Page: 99

Submitted: 2 March 2014; Revised: 7 March 2014; Accepted: 8 March 2014; Published online first: 21 March 2014 The guideline ‘Note for guidance on modified release oral and transdermal dosage… Read More »

Top developments in biosimilars during 2013

Published in: Volume 3 / Year 2014 / Issue 1
Author(s):
Page: 46-8

The past year has been a busy one for the biosimilars industry. Perhaps one of the most important milestones during 2013 was the European approval of the first monoclonal antibody… Read More »

Page 1 of 2 1 2 Next »
Go Back Print